for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Basilea Pharmaceutica AG

BSLN.S

Latest Trade

41.38CHF

Change

-0.64(-1.52%)

Volume

28,292

Today's Range

40.74

 - 

42.40

52 Week Range

33.46

 - 

54.10

As of on the SIX Swiss Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
42.02
Open
41.66
Volume
28,292
3M AVG Volume
1.53
Today's High
42.40
Today's Low
40.74
52 Week High
54.10
52 Week Low
33.46
Shares Out (MIL)
10.75
Market Cap (MIL)
499.20
Forward P/E
-15.67
Dividend (Yield %)
--

Next Event

Basilea Pharmaceutica AG at Kepler Cheuvreux Biotech Days

Latest Developments

More

Basilea Pharmaceutica Says H1 Net Loss Narrows To CHF 15.4 Mln

Basilea Extends Phase 2 Study With Derazantinib In Intrahepatic Bile Duct Cancer

Basilea Pharmaceutica FY Net Loss Widens To CHF 31.4 Million

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Basilea Pharmaceutica AG

Basilea Pharmaceutica AG is a Switzerland-based company engaged in the research, development and commercialization of pharmaceutical products. The Company focuses on pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology. The Company has a range of drugs to treat drug-resistant bacterial infections, systemic fungal infections and drug-resistant tumors. The Company’s anti-infectives, including isavuconazole and ceftobiprole are in late-stage clinical development, while the novel antibiotic, BAL30072 and the oncology compound, BAL101553 are in clinical phase I. The Company’s subsidiaries include Basilea Pharmaceutica China Ltd., Basilea Pharmaceuticals A/S, Basilea Pharma SAS, Basilea Pharmaceutica Deutschland GmbH, Basilea Pharmaceutica International Ltd., BPh Investitionen Ltd., Basilea Medical Ltd. and Basilea Pharmaceuticals Ltd.

Industry

Biotechnology & Drugs

Contact Info

Grenzacherstrasse 487

+41.61.6061111

http://www.basilea.com/

Executive Leadership

Domenico Scala

Chairman of the Board of Directors

David Veitch

Chief Executive Officer, Member of the Management Committee

Adesh Kaul

Chief Financial Officer

Gerrit Hauck

Chief Technology Officer

Laurenz Kellenberger

Member of the Management Committee, Chief Scientific Officer

Key Stats

1.75 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, CHF)

2016

0.1K

2017

0.1K

2018

0.1K

2019(E)

0.1K
EPS (CHF)

2016

-5.070

2017

-1.790

2018

-2.890

2019(E)

-2.682
Price To Earnings (TTM)
--
Price To Sales (TTM)
4.43
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-12.21
Return on Equity (TTM)
-8.96

Latest News

Latest News

BRIEF-Basilea Pharmaceutica Says H1 Net Loss Narrows To CHF 15.4 Mln

* BASILEA REPORTS SIGNIFICANTLY INCREASED CASH-GENERATING REVENUE, FLAT OPERATING EXPENSES AND REDUCED NET LOSS FOR HALF-YEAR 2019

BRIEF-Basilea Starts Phase 1/2 Study With Derazantinib In Urothelial Cancer

* BASILEA STARTS PHASE 1/2 STUDY WITH DERAZANTINIB IN UROTHELIAL CANCER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Basilea Extends Phase 2 Study With Derazantinib In Intrahepatic Bile Duct Cancer

* BASILEA EXTENDS PHASE 2 STUDY WITH DERAZANTINIB IN INTRAHEPATIC BILE DUCT CANCER (ICCA) TO INCLUDE PATIENTS WITH FGFR2 GENE MUTATIONS OR AMPLIFICATIONS

BRIEF-Basilea Pharmaceutica Publishes Clinical Data For Anticancer Drug Candidates BAL101553

* REPORTS PUBLICATION OF CLINICAL DATA FOR ANTICANCER DRUG CANDIDATES BAL101553 IN GLIOBLASTOMA AND DERAZANTINIB IN INTRAHEPATIC CHOLANGIOCARCINOMA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Basilea Pharmaceutica FY Net Loss Widens To CHF 31.4 Million

* BASILEA REPORTS STRONG REVENUE GROWTH AND SIGNIFICANT PIPELINE PROGRESS FOR FULL-YEAR 2018

BRIEF-Basilea Pharmaceutica: Strong European Cresemba Sales Trigger $5 Mln Milestone Payment

* STRONG EUROPEAN CRESEMBA® (ISAVUCONAZOLE) SALES TRIGGER USD 5 MILLION MILESTONE PAYMENT TO BASILEA FROM PFIZER

BRIEF-Basilea Says Adesh Kaul Appointed CFO

* BASILEA ANNOUNCES CHANGE IN THE MANAGEMENT COMMITTEE - ADESH KAUL APPOINTED CFO

BRIEF-Basilea Announces Collaboration To Study Derazantinib And Atezolizumab In Urothelial Cancer

* BASILEA ANNOUNCES COLLABORATION TO STUDY DERAZANTINIB AND ATEZOLIZUMAB (TECENTRIQ®) IN UROTHELIAL CANCER

BRIEF-Basilea Announces Collaboration To Study Derazantinib And Atezolizumab In Urothelial Cancer

* BASILEA ANNOUNCES COLLABORATION TO STUDY DERAZANTINIB AND ATEZOLIZUMAB (TECENTRIQ®) IN UROTHELIAL CANCER

BRIEF-Basilea: Positive Interim Results From Registrational Phase 2 Study With Derazantinib

* BASILEA REPORTS POSITIVE INTERIM RESULTS FROM REGISTRATIONAL PHASE 2 STUDY WITH ONCOLOGY DRUG CANDIDATE DERAZANTINIB IN INTRAHEPATIC CHOLANGIOCARCINOMA (ICCA)

BRIEF-Basilea Preliminary FY Revenue At CHF 133 Mln

* BASILEA REPORTS STRONG, HIGHER THAN EXPECTED PRELIMINARY REVENUE OF CHF 133 MILLION FOR FINANCIAL YEAR 2018

BRIEF-Basilea Pharmaceutica: CHF 10 Million Milestone Payment For Cresemba Sales

* CONTINUED STRONG CRESEMBA® (ISAVUCONAZOLE) U.S. SALES PERFORMANCE BY ASTELLAS PHARMA INC. TRIGGERS CHF 10 MILLION MILESTONE PAYMENT TO BASILEA

BRIEF-Basilea Presents Preclinical Data On Anticancer Drug Candidate Bal101553 At Eortc-Nci-Aacr Symposium

* BASILEA PRESENTS PRECLINICAL DATA ON ITS ANTICANCER DRUG CANDIDATE BAL101553 AT EORTC-NCI-AACR SYMPOSIUM Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Basilea Pharmaceutica Sees 2018 Oper Loss At CHF 25-35 Mln

* H1 OPERATING LOSS OF CHF 20.4 MILLION COMPARED TO CHF 19.1 MILLION IN H1 2017

BRIEF-Basilea Pharmaceutica: Approval For Antifungal Cresemba (Isavuconazole) In Jordan

* HIKMA PHARMACEUTICALS LLC, GAINED REGULATORY APPROVAL FOR ANTIFUNGAL CRESEMBA (ISAVUCONAZOLE) IN JORDAN Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Basilea Starts Clinical Phase 3 Study With Antibiotic Ceftobiprole In Staphylococcus Aureus Bacteremia

* BASILEA STARTS CLINICAL PHASE 3 STUDY WITH ANTIBIOTIC CEFTOBIPROLE IN STAPHYLOCOCCUS AUREUS BACTEREMIA (SAB) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Basilea Pharmaceutica Reports Receipt Of Payment Based On First Cresemba Approval In Latin America

* REPORTS RECEIPT OF MILESTONE PAYMENT BASED ON FIRST CRESEMBA® APPROVAL IN LATIN AMERICA

BRIEF-Basilea Pharmaceutica Presents Phase 1 Clinical Data With Anticancer Drug Candidate Bal101553

* REPORTS PRESENTATION OF PHASE 1 CLINICAL DATA WITH ANTICANCER DRUG CANDIDATE BAL101553 AT ASCO MEETING

BRIEF-Basilea Pharmaceutica Appoints Gerrit Hauck As CTO

* GERRIT HAUCK APPOINTED AS CHIEF TECHNOLOGY OFFICER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Basilea: Start Of Clinical Phase 3 Study In Japan

* BASILEA REPORTS START OF CLINICAL PHASE 3 STUDY IN JAPAN BY ASAHI KASEI PHARMA WITH ANTIFUNGAL ISAVUCONAZOLE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up